Preload Stress Echocardiography in Aortic Stenosis
of adverse events in patients without high transvalvular flow rate. 8, 9 Recently, our laboratory has developed preload stress echocardiography using leg positive pressure (LPP) to assess cardiac function during preload augmentation. In our previous studies, stroke volume (SV) was significantly increased by LPP in patients with various diseases. 10, 11 Using this increased SV, we can calculate the AVA proj from changes of transvalvular flow rate and AVA during preload augmentation in AS. We hypothesized that AVA proj obtained by preload stress echocardiography would predict cardiac events during follow-up in AS. This clinical research is planned as a proof of concept study, and our study aimed to identify the independent and incremental value of AVA proj to predict event-free survival in LG AS without the need for surgery (ie, without class I or IIa indications).
Methods

Study Population
We designed a single-center prospective study to assess the prognosis in asymptomatic patients with LG AS. Patients with LG AS were defined as having an AVA ≤1.0 cm 2 or AVAi ≤0.6 cm 2 /m 2 and a mean gradient <40 mm Hg. We included asymptomatic or equivocal symptomatic patients with LG AS who underwent preload stress echocardiography from January 2014 to September 2016. Exclusion criteria were (1) depressed LVEF (LVEF <50%); (2) tachyarrhythmia, including atrial fibrillation; (3) moderate/severe aortic or mitral regurgitation or mitral stenosis; (4) known coronary artery disease; (5) uncontrolled hypertension (systolic blood pressure ≥160 mm Hg); (6) unstable clinical condition at the time of echocardiography with optimal medical treatment; (7) planned AVR within 1 month; (8) technically inadequate 2-dimensional and Doppler echocardiograms. We also excluded patients with transvalvular flow rate >250 mL/s at baseline. Projected AVA is an estimate of what would be the AVA at a normal transvalvular flow rate. If the patients had transvalvular flow rate >250 mL/s at baseline, we were unable to calculate the formula of projected AVA. 8, 9 After exclusion, all patients were referred for follow-up medical care at our institute ( Figure 1 ). Patients were divided into 2 groups based on flow status defined by SV index (SVi) as measured by Doppler echocardiography as follows: (1) LG. The LF-LG group corresponded to the diagnosis of paradoxical LF-LG AS. 12, 13 The Institutional Review Board of the Tokushima University Hospital approved the study protocol, and written informed consent was obtained from all subjects. 14 LV volumes were measured by the biplane method of disks using 2-dimensional images. Parameters including AVA were indexed to body surface area. Right ventricular (RV) fractional area change was defined using the formula: (end-diastolic area−endsystolic area)/end-diastolic area×100. Systolic pulmonary artery pressure (SPAP) was measured from the maximal continuous-wave Doppler velocity of the tricuspid regurgitant jet using the systolic transtricuspid pressure gradient calculated by the modified Bernoulli equation. Right atrial pressure was estimated from the inferior vena cava diameter and collapsibility. 15 Peak systolic longitudinal strain measurements were obtained from gray-scale images recorded in the apical 4-chamber, 2-chamber, and long-axis views. The frame rate was maintained at a level >40 frame/s. LV strain was analyzed offline using speckle tracking software (EchoInsight; Epsilon Imaging, Ann Arbor, MI). Global longitudinal strain was obtained by averaging all segmental strain values from the apical 4-chamber, 2-chamber, and long-axis views. Valvuloarterial impedance (Zva) was calculated as follows: (systolic blood pressure+mean gradient)/SVi. Mean transvalvular flow rate (Q) was calculated as follows: SV/LV ejection time.
Standard Echocardiography
Stress Echocardiography
All patients underwent preload stress echocardiography. We customized a commercially available leg-massage machine (Dr Medomer DM-5000EX; Medo Industries Co, Ltd, Tokyo, Japan) and used a setting of 90 mm Hg based on findings from our studies. 10, 11 All echocardiographic variables were obtained at baseline and during LPP (Movie I in the Data Supplement). All patients tolerated 90 mm Hg LPP without any complications. The projected AVA was calculated in each patient by the following equation as previously described and validated in several articles. 
Outcomes
All patients were followed in our hospital (clinical follow-up visits at least every 3 months). The treating cardiologists were blinded to the results of AVA proj . The duration of follow-up was begun at the time of the initial tests and ended in March 2017. The primary end point was the decision for AVR or cardiac death. The decision for AVR was made by the patient's physician based on the development of symptoms, the occurrence of acute pulmonary edema, or the development of LV dysfunction.
Statistical Analysis
Data are presented as mean±SD if the Kolmogorov-Smirnov test showed a normal distribution. Otherwise, the median and interquartile ranges were used. Continuous variables were compared using an unpaired Student t or Mann-Whitney U test as appropriate, whereas categorical variables were compared using the χ 2 or Fisher exact test, as appropriate. Changes in continuous variables from baseline to during LPP were analyzed using repeated-measures ANOVA. One-way ANOVA analysis for repeated measures was used to compare echocardiographic parameters between groups. Bonferroni correction was used for post hoc analysis of significant results. The association of several parameters with end points was identified by Cox proportional-hazards models in univariable and multivariable analyses. Clinical and echocardiographic variables were incorporated into the multivariable models using a stepwise variable selection method in which variables were either entered or removed if P<0.05 or P>0.1, respectively. Sequential Cox models were performed to determine the incremental prognostic benefit of AVAi proj and echocardiographic parameters during LPP compared with the baseline model with incremental prognostic value being defined by a significant increase in global χ 2 . A hazard ratio with a 95% confidence interval (CI) was calculated for each variable. The assumption of proportional hazards was assessed by plotting the scaled Schoenfeld residuals for each independent variable against time; these correlations were found to be nonsignificant. Time-dependent receiver operating characteristic curves were used to determine optimal cutoff values of continuous variables using the R package survival ROC. 16 The optimal cutoff value was defined as the upper limit of the CI of the Youden index. The DeLong method was used to compare the C statistic. 17 To assess prognostic value, the optimal cutoff value of AVAi proj was used to divide patients into 2 groups for Kaplan-Meier analysis, with event-free survival compared using a 2-sided log-rank test. The improvement in predictive accuracy was evaluated by calculating the net reclassification improvement using the R package PredictABEL. We conducted bootstrapping with 2000 resamples to assess the internal validation. 
Results
Patient Characteristics
Baseline characteristics are presented in Table 1 . The study population consisted of 79 patients (77±7 years; 30% men) with LG AS with preserved LVEF. In this cohort, 47 patients (59%) were diagnosed with NF-LG AS, and 32 patients (41%) were diagnosed with LF-LG AS. There was no statistically significant difference of clinical characteristics, including medication and comorbidity, between the 2 groups.
Echocardiographic Parameters at Baseline and During Preload Augmentation
Echocardiographic data at baseline and during LPP are shown in Table 1 . LVEF was preserved (66±4%), but global longitudinal strain was relatively decreased (−17±2%). 18 In the aortic valve profiles, AVAi in LF-LG was smaller than that in NF-LG (0.47±0.12 cm 2 /m 2 versus 0.53±0.08 cm 2 /m 2 ; P<0.001). At baseline, patients in LF-LG cohort had significantly lower LVEF, lower RV fractional area change, higher SPAP, and higher Zva profiles than patients in the NF-LG cohort. During LPP, patients with LF-LG also had significantly lower LVEF, lower RV fractional area change, higher SPAP, lower global longitudinal strain, and higher Zva profiles than patients in the NF-LG cohort. The average AVAi proj was 0.70±0.15 cm LG. In this cohort, flow rate was significantly increased from 182±28 mL/sec to 203±31 mL/sec during LPP (P<0.001). The blood pressure slightly increased during LPP (P=0.04). However, the heart rate and the Zva did not change during LPP (P for heart rate, 0.33 and P for Zva, 0.06). Thus, LPP can increase preload without significant increasing of LV afterload. SV index, AVA, and AVA index were significantly increased during LPP in both NF-LG and LF-LG groups (P<0.001; Figure 3 ).
Prediction for Event-Free Survival
During a period of 19 months (range, 6-36 months), 23 (29%) patients experienced the primary end point. The decision for AVR was driven by the occurrence of symptoms alone in 7 patients (5 patients had New York Heart Association IIm, and 2 patients had New York Heart Association III), the occurrence of acute pulmonary edema with symptoms in 14 patients confirmed by chest radiograph (10 patients had New York Heart Association III, and 4 patients had New York Heart Association IV), and the development of LV dysfunction in 2 patients. No patient died. In all patients with the decision for AVR, severe AS has been confirmed by transesophageal echocardiography or multislice computed tomography.
The hazard ratios obtained by univariate and multivariable Cox proportional-hazards regression are shown in Table 2 . In univariate analyses, diabetes mellitus, SPAP at baseline and during LPP, Zva at baseline and during LPP, and AVAi proj were associated with the primary end point. Interestingly, flow status (LF-LG or NF-LG) was not associated with the primary end point in this cohort. In a stepwise multivariable analysis, AVAi proj (hazard ratio, 2.00 per 0.1 cm 2 /m 2 decrease; 95% CI, 1.36-2.96; P<0.001) was associated with the primary end point after adjustment for SPAP during LPP and Zva during LPP.
Using receiver operating characteristic curve analysis, we found that the optimal cutoff value of AVAi proj for predicting cardiac events was <0.72 cm 2 /m 2 . Figure 4 illustrates the time to cardiac events stratified according to the optimal value of AVAi proj (0.72 cm . LF-LG seemed to be associated with worse outcome, but there were no significant differences of event-free survival curves between NF-LG and LF-LG (P=0.18). However, patients with small AVAi proj had significantly shorter event-free survival than those with large AVAi proj (P<0.001). In addition, 18-month event-free survivals in patients with large AVAi proj and NF-LG or LF-LG, and with small AVAi proj and NF-LG or LF-LG, were 93%, 100%, 71% and 44%, respectively (P<0.001; Figure I in the Data Supplement). Therefore, smaller AVAi proj was associated with cardiac events independent of flow status.
The incremental benefit of echocardiographic parameters in the prediction of the primary end point is shown in Figure 5 We assessed the internal validation by the bootstrap method and found that the C statistics were similar between our model 3 and the modified model 3 developed using the bootstrap method (C statistics, 0.81; 95% CI, 0.70-0.90 for bootstrap model). Figure 6 shows the comparison of AVAi and AVAi proj between patients with and without events. There were no significant differences of AVAi between patients with and without events (P=0.88). In contrast, AVAi proj in patients with an event was smaller than AVAi proj in patients without an event (P=0.004). By incorporating AVAi proj into AVAi at baseline, continuous net reclassification index for event was 0.48 (95% CI, 0.16-0.95; P=0.04). Data are presented as number of patients (percentage), mean±SD, or median (interquartile range). A indicates late diastolic transmitral flow velocity; ARB/ACEi, angiotensin receptor blocker/angiotensin-converting enzyme inhibitor; AVA, aortic valve area; AVAi, AVA index; AVAiproj, projected AVA index; AVAproj, projected AVA; BP, blood pressure; E, early diastolic transmitral flow velocity; e′, early diastolic mitral annular motion; GLS, global longitudinal strain; HR, heart rate; LPP, leg positive pressure; LVEDVi, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; LF, low flow; LG, low gradient; LVMi, left ventricular mass index; LVSDVi, left ventricular end-systolic volume index; NF, normal flow; Q, mean transvalvular flow rate; RVFAC, right ventricular functional area change; SPAP, systolic pulmonary artery pressure; SVi, stoke volume index; TAPSE, tricuspid annular plane systolic excursion; and Zva, valvuloarterial impedance. 
Discussion
We demonstrated that projected AVAi obtained by preload stress echocardiography was a predictor of the decision for AVR in patients with LG AS. AVAi proj provided incremental prognostic value over echocardiographic parameters during LPP. Importantly, patients with small AVAi proj (cut off, 0.72 cm 2 /m 2 ) had significantly lower event-free survival rates than those with normal AVAi proj . Even if patients with LG AS had preserved LVEF, the additional test should be considered to differentiate the high-risk cohort. The simple but novel application of preload stress echocardiography is a noninvasive technique that can be used to detect a high-risk cohort in LG AS.
Low-Gradient AS
In patients with LG AS, management for surgical intervention remains a matter of debate because of limited data on AVA indicates aortic valve area; CI, confidence interval; E, early diastolic transmitral flow velocity; e′, early diastolic mitral annular motion; GLS, global longitudinal strain; HR, heart rate; LF, low flow; LG, low gradient; LPP, leg positive pressure; LVEF, left ventricular ejection fraction; RVFAC, right ventricular functional area change; SPAP, systolic pulmonary artery pressure; SVi, stoke volume index; and Zva, valvuloarterial impedance.
prognosis. 19 In the guidelines, there is no recommendation, especially for NF-LG AS.
1,2 However, recent meta-analysis revealed that surgical intervention improved the prognosis in patients with paradoxical LF-LG and NF-LG AS compared with conventional management. 4 In addition, compared with surgical AVR, transcatheter AVR is associated with less-frequent and less-severe prosthesis-patient mismatch, particularly in the subset of patients with a small aortic annulus. 20 Thus, with the emergence of the transcatheter AVR, we have to more carefully assess the surgical indication and followup timing of AS. Our study demonstrated that patients with LG AS had a small AVAi proj (<0.72 cm 2 /m 2 ) as a surrogate of high-risk cohort in AS. In a previous study, the AVAi proj by dobutamine or exercise stress tests was associated with worse outcomes. This preceding study showed that the AVAi proj ≤0.55 cm 2 /m 2 was the good cutoff value to predict adverse outcomes in symptomatic LF-LG AS. 9 This result supported our cutoff value because our cohort was early-stage AS, including only asymptomatic or equivocal-symptom patients. Therefore, the assessment of projected AVAi by preload augmentation may hold promise to provide important clinical information. We also showed the prognostic value of Zva and RV function (SPAP) in our cohort. There has recently been increasing recognition of the prognostic information provided by Zva and A B RV function in valvular disease. 21, 22 Our results in this study are consistent with previous works linking Zva and RV function with cardiac events in patients with AS.
Comparison Between NF and LF-LG AS
In this study, patients with LF-LG AS had lower LV systolic function (LVEF and global longitudinal strain), lower RV systolic function (RV fractional area change), higher SPAP, and higher Zva than patients with NF-LG AS. These results suggest that LF-LG AS had particular clinical and hemodynamic features, including LV systolic subtle dysfunction, low cardiac output, and high afterload. Decreased LV systolic function and increased afterload in LF-LG compared with NF-LG might be associated with a trend toward worse mortality in this cohort. More importantly, the AVAi at baseline was not associated with outcomes, and the AVAi proj was strongly associated with outcomes in both groups. The AVAi proj may be more sensitive in assessing actual AS severity in LG AS.
Several studies have demonstrated the use of the measurement for projected AVA during a low-dose dobutamine stress echocardiography to corroborate stenosis severity in patients with LF-LG AS with reduced SVi. 8, 9 In the present study, we have also demonstrated that the dobutamine-derived AVA proj was associated with the prognosis in the small group of patients with LF-LG AS. The dobutamine stress echocardiography is a useful tool of risk stratification. In our cohort, the LPP-derived AVA proj was also associated with the prognosis. Thus, the use of stress echocardiography is well demonstrated in patients with LF-LG AS. On the contrary, in patients with NF-LG AS, the SV is normal at rest, and the measuring AVA proj in AS patients with NF-LG had not well been evaluated previously. However, some of patients with NF-LG have an actual low pressure gradient state with a prolongation of the ejection time. In such cases, they may have abnormal valve leaflet morphology or mobility. Thus, the standardized valve area at NF rate may be useful for comparing valve compliance in patients with various flow statuses assessed by echocardiography. Actually, the AVA proj was well associated with outcomes of NF-LG AS in this present study. We believed that AVA proj can be used to assess the actual severity of NF-LG AS.
Effects of Preload Augmentation
The projected AVA was a novel concept of assessment for AS severity. 9 In the clinical setting, the flow rate sometimes did not reach the normal range even during the dobutamine stress test to assess AS severity. In these patients, the projected AVA 
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can be calculated at an NF rate (250 mL/sec) using the previously described formula. This method had the advantage of not needing to reach the NF rate during the stress test. In our previous studies, a response to preload augmentation was an increase in SV according to Frank-Starling law. Using our method, the averaged percentage of increased flow rate was 11%. This small increased flow rate was a major limitation of this study. According to previous studies, a minimum of 15% increase in flow rate was needed to obtain a reliable estimate of the projected AVA during dobutamine testing. 23 We tried to overcome the limitation by comparing the result of preload stress with the dobutamine stress test. There was a good correlation between dobutamine-derived and LPP-derived values of AVA proj (r=0.93; P<0.001). Thus, we believed that LPPderived AVA proj value was acceptable for the assessment of AS. This finding is well matched with the concept that AVA proj during augmentation of SV is an important phenomenon for assessing the severity of LG AS.
There are several advantages of preload stress echocardiography compared with exercise or dobutamine stress echocardiography. Dobutamine infusion leads to hypercontraction and systolic obstruction of the LV outflow tract in some cases. On the contrary, preload augmentation does not cause the obstruction of LV outflow tract. The LPP constantly provides a stable pressure to both lower limbs and augment a stable preload stress. The preload stress is removed immediately when the switch is turned off. In our study, we could perform the LPP during echocardiography in all the subjects. It is a safe, reversible, and reproducible maneuver for increasing preload stress.
Clinical Implications
This is the first investigation of projected AVA during preload augmentation to differentiate LG AS patients with high risk of the need for AVR. Current consensus for AS described the stress echocardiography in LG AS to assess the severity of disease state. 24 However, those invasive tests are underused in the clinical setting because of the risk of stress, expense of equipment, time, and capability. Our preload stress echocardiography is a safe and easy method to evaluate the risk of cardiac events in patients with AS. If patients had small AVA proj using preload stress echocardiography, they would have an additional test, including computed tomography or transesophageal echocardiography. Computed tomography and transesophageal echocardiography can assess the quantification of calcification in the region of the aortic valve and the anatomic suitability for transcatheter AVR. Thus, these additional tests should be considered to confirm as severity and determine the need for surgical AVR or transcatheter AVR in the high-risk group defined by preload stress echocardiography (Figure 8 ).
Limitations
The sample size was small, with relatively few soft events, which poses a potential risk of model overfit. Our cohort consisted of asymptomatic patients with LG AS, and the rate of cardiac death is relatively low before the occurrence of symptoms. However, once a patient becomes symptomatic in AS, it shows a rapid disease progression. We thought it is crucial to detect an early stage of severe AS before the occurrence of LV dysfunction or cardiac death in the clinical setting. Thus, we decided the primary end point was the decision to perform AVR. SV was measured on the basis of echocardiographic parameters, which have inherent measurement variability. Although there was a good correlation between dobutaminederived and LPP-derived AVA proj in a subset of the group, a possibility of misclassification for AS severity existed because of the small increase of SV during LPP. However, LPP-derived AVA proj was well associated with outcomes in this cohort. We think that this method will work in the clinical setting. Finally, we have not assessed the external validation of our model. According to these limitations, the present study should be considered as a proof of concept, and we think that larger prospective multicenter studies are warranted.
Conclusions
AVAi proj derived by preload augmentation was a powerful predictor of the decision for AVR in LG AS. Preload stress echocardiography is a useful method for identifying a subgroup with high-risk patients of cardiac events. 
